These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 21964801)

  • 1. Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors.
    Morita S; Oizumi S; Minami H; Kitagawa K; Komatsu Y; Fujiwara Y; Inada M; Yuki S; Kiyota N; Mitsuma A; Sawaki M; Tanii H; Kimura J; Ando Y
    Invest New Drugs; 2012 Oct; 30(5):1950-7. PubMed ID: 21964801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors.
    Sharma S; Beck J; Mita M; Paul S; Woo MM; Squier M; Gadbaw B; Prince HM
    Invest New Drugs; 2013 Aug; 31(4):974-85. PubMed ID: 23377661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.
    DeAngelo DJ; Spencer A; Bhalla KN; Prince HM; Fischer T; Kindler T; Giles FJ; Scott JW; Parker K; Liu A; Woo M; Atadja P; Mishra KK; Ottmann OG
    Leukemia; 2013 Aug; 27(8):1628-36. PubMed ID: 23385375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors.
    Fukutomi A; Hatake K; Matsui K; Sakajiri S; Hirashima T; Tanii H; Kobayashi K; Yamamoto N
    Invest New Drugs; 2012 Jun; 30(3):1096-106. PubMed ID: 21484248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
    Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
    Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function.
    Slingerland M; Hess D; Clive S; Sharma S; Sandstrom P; Loman N; Porro MG; Mu S; Waldron E; Valera SZ; Gelderblom H
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1089-98. PubMed ID: 25253045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma.
    Thomas S; Aggarwal R; Jahan T; Ryan C; Troung T; Cripps AM; Raha P; Thurn KT; Chen S; Grabowsky JA; Park J; Hwang J; Daud A; Munster PN
    Ann Oncol; 2016 May; 27(5):947-52. PubMed ID: 26903311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors.
    Bauer S; Hilger RA; Mühlenberg T; Grabellus F; Nagarajah J; Hoiczyk M; Reichardt A; Ahrens M; Reichardt P; Grunewald S; Scheulen ME; Pustowka A; Bock E; Schuler M; Pink D
    Br J Cancer; 2014 Mar; 110(5):1155-62. PubMed ID: 24434430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.
    San-Miguel JF; Richardson PG; Günther A; Sezer O; Siegel D; Bladé J; LeBlanc R; Sutherland H; Sopala M; Mishra KK; Mu S; Bourquelot PM; Victoria Mateos M; Anderson KC
    J Clin Oncol; 2013 Oct; 31(29):3696-703. PubMed ID: 24019544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
    Xia C; Leon-Ferre R; Laux D; Deutsch J; Smith BJ; Frees M; Milhem M
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):691-7. PubMed ID: 25062770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function.
    Sharma S; Witteveen PO; Lolkema MP; Hess D; Gelderblom H; Hussain SA; Porro MG; Waldron E; Valera SZ; Mu S
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):87-95. PubMed ID: 25377157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer.
    Rathkopf DE; Picus J; Hussain A; Ellard S; Chi KN; Nydam T; Allen-Freda E; Mishra KK; Porro MG; Scher HI; Wilding G
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):537-44. PubMed ID: 23820963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors.
    Savelieva M; Woo MM; Schran H; Mu S; Nedelman J; Capdeville R
    Eur J Clin Pharmacol; 2015 Jun; 71(6):663-672. PubMed ID: 25939707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study.
    Takahashi S; Fujiwara Y; Nakano K; Shimizu T; Tomomatsu J; Koyama T; Ogura M; Tachibana M; Kakurai Y; Yamashita T; Sakajiri S; Yamamoto N
    Cancer Sci; 2021 Jun; 112(6):2361-2370. PubMed ID: 33686772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients.
    Tan WW; Allred JB; Moreno-Aspitia A; Northfelt DW; Ingle JN; Goetz MP; Perez EA
    Clin Breast Cancer; 2016 Apr; 16(2):82-6. PubMed ID: 26774555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF).
    Mascarenhas J; Lu M; Li T; Petersen B; Hochman T; Najfeld V; Goldberg JD; Hoffman R
    Br J Haematol; 2013 Apr; 161(1):68-75. PubMed ID: 23330839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
    Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
    Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.
    Rathkopf D; Wong BY; Ross RW; Anand A; Tanaka E; Woo MM; Hu J; Dzik-Jurasz A; Yang W; Scher HI
    Cancer Chemother Pharmacol; 2010 May; 66(1):181-9. PubMed ID: 20217089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.
    Berenson JR; Hilger JD; Yellin O; Boccia RV; Matous J; Dressler K; Ghazal HH; Jamshed S; Kingsley EC; Harb WA; Noga SJ; Nassir Y; Swift RA; Vescio R
    Ann Hematol; 2014 Jan; 93(1):89-98. PubMed ID: 24135804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report.
    Fouladi M; Park JR; Stewart CF; Gilbertson RJ; Schaiquevich P; Sun J; Reid JM; Ames MM; Speights R; Ingle AM; Zwiebel J; Blaney SM; Adamson PC
    J Clin Oncol; 2010 Aug; 28(22):3623-9. PubMed ID: 20606092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.